Loss ofrasOncogene Mutation in a Myelodysplastic Syndrome after Low-Dose Cytarabine Therapy
- 2 June 1988
- journal article
- Published by Massachusetts Medical Society in New England Journal of Medicine
- Vol. 318 (22) , 1468-1469
- https://doi.org/10.1056/nejm198806023182215
Abstract
To the Editor: The myelodysplastic syndromes are a group of hematopoietic stem-cell disorders characterized by cytopenia due to defective erythroid, myeloid, and megakaryocytic maturation.1 Transformation to acute nonlymphocytic leukemia occurs in 30 percent of all cases. Mutational activation of ras oncogenes occurs frequently in acute nonlymphocytic leukemia.2 Recently, mutations of N-ras and Ki-ras have been identified in myelodysplastic syndromes.3 , 4 Genes of the human ras family are believed to play a part in the transduction of receptor-mediated signals across the cell membrane.5 Their activation in human tumors by single nucleotide alterations at codons 12, 13, and 61 with corresponding . . .Keywords
This publication has 7 references indexed in Scilit:
- Mutations of the Kirsten-ras proto-oncogene in human preleukaemiaNature, 1987
- A point mutation at codon 13 of the N-ras oncogene in myelodysplastic syndromeNature, 1987
- Mutations in N-ras predominate in acute myeloid leukemiaBlood, 1987
- In vivo differentiation of leukaemic blasts and effect of low dose Ara-C in a marrow grafted patient with leukaemic relapseBritish Journal of Haematology, 1986
- Normal and activated ras oncogenes and their encoded productsTrends in Genetics, 1986
- Enzymatic Amplification of β-Globin Genomic Sequences and Restriction Site Analysis for Diagnosis of Sickle Cell AnemiaScience, 1985
- Treatment of preleukemic syndromes with continuous intravenous infusion of low-dose cytosine arabinoside.Journal of Clinical Oncology, 1985